Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced...
Transcript of Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced...
![Page 1: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/1.jpg)
Updates in Gynecologic Cancer Care
Margaret Liang, MD, MSHS
Division of Gynecologic Oncology
University of Alabama at Birmingham
ACC-MOS Joint Spring Meeting
April 13, 2019
![Page 2: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/2.jpg)
Disclosures
• Dr. Liang has no disclosures
• Off label utilization of cancer therapeutics will be mentioned. The view(s) expressed herein are those of the speaker and do not reflect the official policy or position of University of Alabama at Birmingham
![Page 3: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/3.jpg)
UAB Division of Gynecologic Oncology
![Page 4: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/4.jpg)
OvarianCancer
Ovarian cancer 22,240
Siegel et al. CA Cancer J Clin, 2018.
![Page 5: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/5.jpg)
Advanced ovarian cancer
• Cornerstone of treatment – combo of surgery and chemotherapy
• Aggressive optimal debulking surgery to <1 cm and ideally to no gross residual disease (R0)
• Platinum/taxane doublet chemotherapy
• Platinum sensitivity is a prognostic factor
![Page 6: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/6.jpg)
Role of neoadjuvant chemotherapy
• 2 RCTs demonstrating neoadjuvant chemotherapy (NACT) approach is non-inferior to primary debulking surgery (PDS) in terms of PFS and OS for patients with advanced ovarian cancer• EORTC
• CHORUS
• NACT approach associated with less perioperative morbidity and mortality
Vergote et al. NEJM, 2010.Kehoe et al. Lancet Oncol, 2015.
![Page 7: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/7.jpg)
RCTs evaluating neoadjuvant chemotherapyEORTC
PDSEORTCNACT
CHORUSPDS
CHORUSNACT
Number of patients 361 357 255 219
Residual ≤ 1 cm 42% 81% 41% 73%
No gross residual 18% 45% 17% 39%
PFS 12 months 12 months 11 months 12 months
OS 29 months 30 months 23 months 24 months
Postop complications24%
any grade 3/414%
any grade 3/4
7%, 8%, 3% (grade 3/4
hemorrhage, infection, venous)
4% , 2%, 0%(grade 3/4
hemorrhage, infection, venous)
Death within 30 days of surgery 6% 1% 3% 1%
Vergote et al. NEJM, 2010.Kehoe et al. Lancet Oncol, 2015.
![Page 8: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/8.jpg)
Planned pooled analysis EORTC/CHORUS trials
OSHR 0.97 (95% CI 0.86-1.09)
PFSHR 0.98 (95% CI 0.87-1.10)
Vergote et al. Lancet Oncol, 2018.
![Page 9: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/9.jpg)
Subgroup analysis suggests NACT for stage IV and PDS for stage IIIC without bulky disease
OS for stage IV diseaseHR 0.76 (95% CI 0.58-1.00)
PFS for stage IIIC diseasewith tumor <5 cm
HR 1.36 (95% CI 1.06-1.75)
Vergote et al. Lancet Oncol, 2018.
![Page 10: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/10.jpg)
If cannot obtain biopsy cytologic evaluation (i.e., ascites, pleural effusion) combined with serum CA-125 to CEA ratio >25 acceptable
RCTs tested interval cytoreductive surgery following 3-4 cycles of chemotherapy
CT imaging to evaluate extent of disease and GYN ONC consult to evaluate surgical risk/resectability
Platinum/taxane doublet
Wright et al. J Clin Oncol, 2016.
![Page 11: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/11.jpg)
Increasing Use of NACT Approach
• High perioperative risk:- Low albumin esp. if need bowel resection
- Recent VTE
- Poor ECOG performance status
• Optimal cytoreduction unlikely:• Mesenteric involvement
• Porta hepatis
• Pulmonary involvement
• Laparoscopic scoring
Melamed et al. Gynecol Oncol, 2016.
Using the National Cancer Database (NCDB)2004-2013
![Page 12: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/12.jpg)
Laparoscopic scoring to determine resectability
Fagotti score components
2 points for each
Peritoneal carcinomatosis
Massive/unresectable + miliary distribution
Diaphragmatic disease Infiltrating/widespread, confluent nodules
Mesenteric disease Infiltrating/widespread, root of mesentary
Omental disease Up to greater curvature
Bowel infiltration Bowel resection assumed to be required
Stomach infiltration Gastric wall involved
Liver metastasis Any surface lesions
Score ≥ 8 was was associated with 0% probability of optimal resection
(113 patients in prospective cohort)
Avoided 40% of unnecessary laparotomies
Fagotti et al. Am J Obstet Gynecol, 2008.
![Page 13: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/13.jpg)
Treatment Landscape for Ovarian Cancer Is Rapidly Changing
https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed March 29 and April 9, 2018. Kelland et al. Nat Rev Cancer, 2007.
Primary
Landmark FDA approvals in ovarian cancer therapy
Maintenance
1978 2017
Cisplatin2 Carboplatin2
(1L)
Paclitaxel
Topotecan
Liposomal Doxorubicin (Accelerated)
Liposomal Doxorubicin
(Full)
Gemcitabine
Bevacizumab (platinum-resistant)
Olaparib(BRCAmut carriers)
Bevacizumab (platinum-sensitive)
Rucaparib (somatic + germline BRCAmut)
Niraparib (platinum-sensitive)
Olaparib (platinum-sensitive)
1990 1992 1996 2005 20141991 1999 20061989
Carboplatin2
(palliative)
Altretamine
2018
Rucaparib (platinum-sensitive)
2016
Olaparib(somatic + germline BRCAmut)
![Page 14: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/14.jpg)
Intraperitoneal (IP) chemo - GOG 172
Median PFS 18.3 vs. 23.8 months (p=0.05) Median OS 49.7 vs. 65.6 months, p=0.03
Armstrong et al. NEJM, 2006.
![Page 15: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/15.jpg)
IP chemo in the real world
• GOG 172:• IV chemo arm: D1 IV taxol 135 mg/m2 over 24h + D2 75 mg/m2 IV cisplatin
• IP chemo arm: D1 IV taxol 135 mg/m2 over 24h + D2 100 mg/m2 IP cisplatin + D8 60 mg/m2 IP taxol
• Only 42% completed all 6 cycles
• The real world:• IV taxol usually given over 3 hours
• Drug modifications - estimated 43% of NCCN institutions use modified regimen (i.e., IV drug substitution, IP drug substitution, IP dose reduction)
• Intensive management of side effects (i.e., dehydration, IP port malfunction, abdominal distention, nausea/vomiting, renal dysfunction)
Armstrong et al. NEJM, 2006. Wright et al. J Clin Oncol, 2015.
![Page 16: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/16.jpg)
Trends in NACT and IP chemotherapy
Stage IIIC disease Stage IV disease
Meyer et al. J Clin Oncol, 2016.
![Page 17: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/17.jpg)
Dose-dense taxol/carbo – JGOG 3016
Katsumata et al. Lancet Oncol, 2013.
PFSHR 0.76 (95% CI 0.62-0.91)
28.2 months vs. 17.5 months
OSHR 0.79 (95% CI 0.63-0.99)
100.5 months vs. 62.2 months
![Page 18: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/18.jpg)
Dose-dense regimen after suboptimal debulking – JGOG 3016
Katsumata et al. Lancet Oncol, 2013.
PFS OS
SuboptimalSuboptimal
Optimal
Optimal
![Page 19: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/19.jpg)
Dose-dense taxol/carbo - GOG 262
Chan et al. NEJM, 2016.
![Page 20: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/20.jpg)
Dose-dense taxol/carbo - GOG 262
Chan et al. NEJM, 2016.
In those who did not receive bevacizumab, weekly taxol extended PFS by 3.9 months
![Page 21: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/21.jpg)
Dose-dense regimens
• JGOG 3016• Conventional arm: D1 carboplatin AUC 6 + taxol 180 mg/m2
• Dose-dense arm: D1 carboplatin AUC 6 + taxol 80 mg/m2 on D1, 8, 15• Included stage II-IV, gave 6 cycles (but could add 3 additional cycles if
measurable lesions with PR or CR)• Asian patients with better survival than prior trials in USA/Europe
• GOG 262 • Same arms but could add bevacizumab 15 mg/kg q21 days starting cycle 2
• 85% opted in
• Stratified based on bevacizumab use (patient/provider selection)• Included stage II-IV, gave 6 cycles
![Page 22: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/22.jpg)
Bevacizumab in upfront setting – GOG 218
![Page 23: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/23.jpg)
Bevacizumab in upfront setting – GOG 218
Primary endpoint: PFSHR 0.72 (95% CI 0.63-0.82)
14.1 vs. 10.3 months
No difference in OS on final analysis
BEV-throughout compared to controlHR 0.96 (95% CI 0.85-1.09)
BEV-initiation compared to controlHR 1.06 (95% CI 0.94-1.20)
Median OS for stage IV BEV-throughout (42.8 months) similar to median OS for
stage III patients in all 3 arms (44.3 months, 42.9 months, 44.2 months)
Burger et al. NEJM, 2011.Burger et al. ASCO, 2018.
![Page 24: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/24.jpg)
Testing too many hypotheses? GOG 252
Walker et al. SGO 2016.
![Page 25: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/25.jpg)
GOG 252 – No difference in PFS
![Page 26: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/26.jpg)
HR Proficient
~47%
Non-BRCA
HR Deficient
~33%
Germline
BRCAmut
~14%
Somatic
BRCAmut
~6%
Beyond BRCA mutations – homologous recombination deficiency (HRD)
Konstantinopoulos et al. Cancer Discov, 2015.
~50% high grade serous ovarian cancer patients have HRD which may also determine potential benefit from
targeted therapies
![Page 27: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/27.jpg)
PARP Inhibitors Yield Synthetic Lethality in Patients With HRD• PARP inhibitors prevent repair of single-strand breaks, which accumulate and generate double-strand breaks
• People with HRD cannot repair double-strand breaks, which triggers cell death
HRD, homologous recombination deficiency; PARP, poly ADP ribose polymerase.
Sonnenblick A, et al. Nat Rev Clin Oncol. 2015;12(1):27-41.
Single-strand break
PARP
PARP inhibitors
Double-strand breaks
Repair by homologous recombination
No homologousrecombination or repair
Cell survival Cell death DNA repaired
Normal Cell Cell with HRD
Sonnenblick et al. Nat Rev Clin Oncol, 2015.
![Page 28: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/28.jpg)
FDA approved PARP inhibitorsOlaparib Rucaparib Niraparib
2014 Recurrence treatmentgBRCA3 or more prior linesStudy 19
2016 Recurrence treatmentgBRCA or sBRCA2 or more prior linesARIEL 2
2017 Recurrence maintenancegBRCA or sBRCAPlatinum sensitiveSOLO 2
Recurrence maintenancePlatinum sensitive2 or more prior linesNOVA
2018 Primary maintenancegBRCA or sBRCASOLO 1
Recurrence maintenancePlatinum sensitive2 or more prior linesARIEL 3
![Page 29: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/29.jpg)
PARP inhibitor toxicities and MDS risk
Moore K. SGO Distillation, 2019.Matulonis et al. SGO, 2019.
![Page 30: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/30.jpg)
PARP inhibitor dose reductionsOlaparib100 mg (tablet)150 mg (tablet)
Rucaparib300 mg (tablet)250 mg (tablet)200 mg (tablet)
Niraparib100 mg (capsule)
Starting dose 300 mg PO BID 600 mg PO BID 300 mg PO daily
First dose reduction 250 mg PO BID 500 mg PO BID 200 mg PO daily*(start at this dose if <77 kg or plt <150K)
Second dose reduction
200 mg PO BID 400 mg PO BID 100 mg PO daily
Third dose reduction
300 mg PO BID
![Page 31: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/31.jpg)
SOLO 1 – PARP inhibitor maintenance in the upfront setting
Moore et al. ESMO, 2018.
![Page 32: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/32.jpg)
Testing paradigms – timing of germline and somatic testing
Moore K. SGO Distillation, 2019.Would miss ~5% of germline BRCA if relied on somatic testing alone
![Page 33: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/33.jpg)
Fallopian tube as the origin of ovarian cancer
• BRCA mutation carriers undergoing risk-reducing salpingo-oophorectomy (RRSO)• SEE-FIM protocol: Sectioning and Extensive Examining of the FIMbria
• Precursor lesions:• p53 signature• STIC lesions (serous tubal intraepithelial carcinoma) – present in 50-60% of
high grade serous ovarian cancers Perets et al. Cancer Res, 2016.
![Page 34: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/34.jpg)
Prophylactic salpingectomy in women at high-risk for ovarian cancer
TUBA (Netherlands) WISP (USA)
Strategy RRSO age 35-40 for BRCA1RRSO age 40-45 for BRCA2d-RRO age 40-45 for BRCA1d-RRO age 45-50 if BRCA2
Normal pelvic US and CA-125 within 6 months
N 384 (50) 190 (270)
BRCA1/BRCA2 51%/49% 51/39%
Selected d-RRO 72% 52%
Primary outcome Menopause-related QOL Change in sexual function using FSFI (female sexual function index)
Future trials will be needed to determine efficacy (n=3000) Lu et al. SGO, 2019.Steenbeek et al. SGO, 2019Herzog. SGO Distillation, 2019.
![Page 35: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/35.jpg)
Opportunistic salpingectomy
• Salpingectomy at time of gynecologic surgical procedure (i.e., hysterectomy) or as permanent sterilization technique
• Opportunity to decrease (but not eliminate) ovarian cancer
• Does not blood supply to the ovaries
• Should not alter the surgical approach to surgery
![Page 36: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/36.jpg)
CervicalCancer
2007- National HPV vaccination program12/2017- Primary HPV testing q5 years (age 25-69)
Elimination threshold of cervical cancer prediction6 new cases/100,000 by 2020<4 new cases/100,000 by 2028
Hall et al. Lancet Public Health, 2019.
![Page 37: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/37.jpg)
2009 FIGO cervical cancer staging
![Page 38: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/38.jpg)
2018 FIGO cervical cancer staging
Stage IA – lateral extent not considered
Old stage IB1 divided into:Stage IB1 <2 cmStage IB2 2-4cm
New stage IB3 for ≥ 4 cm
New stage IIIC1 (pelvic nodes)New stage IIIC2 (para-aortic nodes)
r for radiologicp for pathologic
If in doubt… use lower stage
![Page 39: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/39.jpg)
Surgical management of early stage cervical cancer – LACC trial
- Stage IA1 (+LVSI), IA2, or IB1 cervical cancer- Randomized to minimally invasive vs. abdominal radical hysterectomy- Primary outcome: disease-free survival at 4.5 years
![Page 40: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/40.jpg)
MIS associated with worse DFS and OS
3-year DFS97.1% MIS vs. 91.2% openHR 3.74 (95% CI 1.63-8.58)
3-year OS99.0% MIS vs. 93.8 open
HR 6.00 (95% CI 1.77-20.30)
![Page 41: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/41.jpg)
Unanswered questions after LACC trial
• What is the mechanism to explain worse survival?• No differences in adjuvant therapy (~30% in both arms)
• Are there a subgroup of appropriate candidates for MIS surgery?• <2 cm• Microscopic
• What about robotic-assisted laparoscopic surgery?• Only 15% were robotic (vs. laparoscopic) in LACC trial• Robotic-assisted approach to cervical cancer (RACC) RCT planned in Sweden
![Page 42: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/42.jpg)
Immunotherapy mechanism of action
An effective antitumor immune response requires:
• Presentation of cancer antigens and activation of T cells
• Trafficking of T cells to tumors and infiltration into tumors
• Killing of tumor cells by T cells
Singh et al Gastroenterology Report, 2015.
![Page 43: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/43.jpg)
Anti-PD1 immunotherapy for cervical cancer
![Page 44: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/44.jpg)
Pembrolizumab – KEYNOTE 158 (basket trial)
• 98 patients with recurrent/metastatic cervical cancer
• Pembrolizumab 200 mg IV every 3 weeks until unacceptable toxicity or progression
• Approval based on 79% of cohort who had PD-L1 + (CPS ≥ 1) who had received at least one line of chemotherapy for metastatic disease
• ORR 14.3% (2.6% CR, 11.7% PR)
• 91% had response duration ≥ 6 months; median response duration not reached
• No responses if CPS <1
• Serious adverse reaction in 39%, discontinued due to adverse reactions in 8%
• Most frequent serious adverse reactions: anemia (7%), fistula (4%), hemorrhage (4%), infections not including UTIs (4%)
![Page 45: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/45.jpg)
Managing immunotherapy toxicities
• Immune-specific toxicity profile• Thyroiditis, hypophysitis, colitis, pancreatitis, pneumonitis, myocarditis, uveitis, arthritis,
hepatitis, vasculitis, nephritis, Guillain-Barre
• Usually develop in first few weeks/months, but can even develop after cessation of therapy
• Dose adjustments are not recommended holding drug or immunosuppression• Grade 2: 0.5 mg/kg/day prednisone
• Grade 3: 1-2 mg/kg/day prednisone
• Infliximab (TNF-alpha inhibitor)
• Most grade 4 toxicities necessitate permanent discontinuation (exception: grade 4 endocrinopathy can sometimes be medically managed)
Brahmer et al. J Clin Oncol, 2018.
![Page 46: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/46.jpg)
UterineCancer
Siegel et al. CA Cancer J Clin, 2018.
![Page 47: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/47.jpg)
The obesity epidemic and its link to endometrial cancer
https://www.cdc.gov/obesity/data/prevalence-maps.html
![Page 48: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/48.jpg)
Sentinel lymph node (SLN) mapping
- Usually only sentinel pelvic lymph node maps, consider para-aortic sampling for high-risk tumors (i.e., grade 3, deep myoinvasion, positive pelvic nodes) especially if would change management i.e., radiation fields
https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
![Page 49: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/49.jpg)
SLN algorithm
• FIRES trial• 385 patients with clinical stage I
endometrial cancer
• Indocyanine green (ICG) dye
• 86% had mapping of at least 1 sentinel node
• Sensitivity 97.2%
• NPV 99.7%
• To minimize false-negatives, perform complete dissection for unmapped sides and remove any suspicious nodes Rossi et al. Lancet Oncol, 2017.
https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
![Page 50: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/50.jpg)
Tumor mutational burden – increased in endometrial cancers
![Page 51: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/51.jpg)
Immunotherapy
Pembrolizumab200 mg IV q3 weeks
(KEYNOTE 016, 164, 012, 028, 158)
MSI-H/dMMR cancern = 149
Endometrial cancern = 14
Objective response rate 39.6%95% CI 32-48%
36%95% CI 13-65%
Median duration of response (months)
NR1.6+, 22.7+ 4.2+, 17.3+
Pembrolizumab package insert
![Page 52: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/52.jpg)
PORTEC-3De Boer et al. Lancet Oncol, 2018.
GOG 258Matei et al. ASCO, 2017
GOG 249Randall et al. ASTRO, 2017.
Population Stage I grade 3 deep invasion and/or LVSI; stage II/III;serous/clear cell
Stage III-IV, optimally debulking Stage I with high-intermediate risk factors (GOG 99) or serous/clearcell), stage II
Treatment arms
RT48.6 Gy in 1.8 Gy fractionsCTRTcisplatin 50 mg/m2 D1, D28 of RT) followed by carbo AUC 5 + taxol715 mg/m2 q21d x 4 cycles
CTcarbo AUC 6 x taxol 175 mg/m2 q21d x 6 cyclesCTRTcisplatin 50 mg/m2 D1, D28 of RT) followed by carbo AUC 5 + taxol715 mg/m2 q21d x 4 cycles
PXRTpelvic radiation 45 Gy or IMRT + boost if serous/clear cell/stage IIVCB/Cvaginal cuff brachy + carbo AUC 6 + taxol 175 mg/m2 x 3 cycles
Results 5-year OS: 77% RT vs. 82% CTRT (HR 0.79 95% CI 0.57-1.12)5-year FFS: 69% vs. 76% (HR 0.77 95% CI 0.58-1.03)
RFS 0.9 (95% 0.74-1.10) 3-year RFS 82% both arms3-year OS 91% PXRT 88% VCB/C
Conclusion Adjuvant chemo did not improve 5-year FFS and OS compared to RT aloneStage III FFS improved with CTRT by 11% at 5 years
No difference in RFS or estimated 5-year OSFewer distant metastases in CT alone group at expense of more vaginal and nodal recurrences
No difference in RFS and OSNo difference in vaginal or distant recurrences (18% distant in both groups)More nodal recurrences in VCB/C
![Page 53: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/53.jpg)
Adjuvant therapy for uterine-limited leiomyosarcoma – GOG 277 unanswered
Chemo arm:Estimated PFS 18.1 monthsEstimated OS 34.3 months
Observation arm: Estimated PFS 14.6 monthsEstimated OS 46.4 months
Closed for accrual futility after 4 years(38/216 enrolled)
Hensley et al. J Clin Oncol, 2018.
![Page 54: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/54.jpg)
Adding olaratumab to doxorubicin for soft tissue sarcoma treatment
• Anti-platelet derived growth factor receptor alpha monoclonal antibody (anti-PDGF) in combination with doxorubicin for unresectable or metastatic soft tissue sarcoma
• 133 patients enrolled in randomized phase II trial
• Approximately 40% study population had leiomyosarcoma
Tap et al. Lancet, 2016.
![Page 55: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/55.jpg)
ANNOUNCE phase III trial does not support use of olaratumab
• Did not meet primary endpoints of OS in the full study population or in the leiomyosarcoma subpopulation
• No new safety signals
• Do not initiate olaratumab outside of a clinical trial
• If currently receiving olaratumab, may continue if patient is receiving benefit and after consultation with their physician
https://investor.lilly.com/node/40206/pdf
![Page 56: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/56.jpg)
ClinicalTrials • On average, FDA drug approval takes…
• $2.6 billion dollars in R&D
• At least 10 years
• Only 1 in 10 drugs tested in phase I trials make it to FDA approval
http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf
![Page 57: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/57.jpg)
Clinical trials Crisis in GYN Cancers
https://www.sgo.org/wp-content/uploads/2012/09/SGO-Clinical-Trial-Crisis-FINAL.pdf
![Page 58: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/58.jpg)
Precision medicine trial designs
![Page 59: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/59.jpg)
Sample of GYN ONC clinical trials at UABPrimaryOvarian
RecurrentOvarian
RecurrentUterine
PrimaryCervical
RecurrentCervical
NACT or PDS:IP GEN-1 with taxol/carboTaxol/carbo +/-metformin/placebo
Platinum resistant:Cedirinib vs. cedirinib/PARP vs. chemo (GY005)Imaging study with weekly taxol + bev
Prior chemo:Olaparib vs. cedirinib vs. olaparib/cedirinib(GY012)Anti-PD1 for MSI-S or MSI-H (GARNET)
Surgical candidate:Cvx SPORE vaccine after completion of primary therapy
Prior GOG 240regimen:Anti-PD1 +/- CTLA4 (GOG3028)
IP cisplatin:antiemetic study
Platinum sensitive:Weekly CDK7i + carbo
Not surgical candidate:Primary chemorads+/- triapine (GY006)Pre-tx atezolizumabprior to primary chemorads (GY017)
![Page 60: Updates in Gynecologic Cancer Care - MemberClicks · 2019-04-22 · OS for patients with advanced ovarian cancer •EORTC •CHORUS ... Chan et al. NEJM, 2016. Dose-dense taxol/carbo](https://reader033.fdocuments.us/reader033/viewer/2022060509/5f2490dff315265d1630bbfc/html5/thumbnails/60.jpg)
To refer a patient for clinical trial eligibility
GYN ONC CLINICAL TRIALS
Trey Leath, MD [email protected]
Rebecca Arend, MD [email protected]
PHASE 1 CLINICAL TRIALS